SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as community members bet on a potential short squeeze, fueled by the imminent acquisition of Northern Data and strategic backing from Tether that many investors believe fundamentally re-rates the company from a video platform to an AI infrastructure powerhouse. Traders are actively debating the impact of upcoming earnings on the heavily shorted float, with bullish sentiment centered on the firm's pivot to high-margin GPU compute and sovereign cloud services.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as investors react to its recent selection for the U.S. Space Force Andromeda IDIQ contract while anticipating upcoming Q1 financial results and potential lunar lander awards. The community is actively debating the company's long-term valuation and revenue potential, with bullish sentiment driven by sector momentum despite continued volatility and short-seller activity.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as investors pivot toward its role as a critical AI networking and infrastructure player, fueled by strategic partnerships with Nvidia and a major expansion into optical networking and 6G-ready tech. The community is actively discussing a potential re-rating of the stock, with bullish sentiment driven by strong call flow and anticipation of upcoming milestone announcements.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco Systems is currently driving significant market interest as it transitions from a legacy networking player into a critical AI infrastructure provider, evidenced by a massive post-earnings rally. The community is actively debating the sustainability of this re-rating, with many drawing parallels to the dot-com era while highlighting the company's aggressive restructuring and AI order growth as evidence of a new growth phase.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma Inc. is trending after reporting over $4 million in U.S. government contracts for its quantum materials and high-speed datacom platform, providing a significant validation of its technology despite ongoing concerns about commercial scaling and current revenue levels. Investors are actively debating the stock's future, weighing potential upside from these high-profile partnerships against the risks of share dilution and the company's path to repeatable manufacturing.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors react to the Phase 3 REGAL trial reaching 78 of 80 required events, sparking intense debate over whether the study's duration indicates improved patient survival or merely a delay. Community discussion is split between bullish sentiment regarding the immunotherapy's potential to trigger a massive short squeeze and bearish skepticism concerning trial modifications, warrant dilution, and historical management transparency.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is currently in focus as investors analyze the firm's progress toward commercializing its silicon-anode battery technology for smartphones and smart eyewear. The community is actively debating the company's qualification timelines and manufacturing yields while weighing the impact of its strategic pivot toward defense and drone markets.

Aurora Innovation, Inc. engages in the design and development of automobile hardware, software, and provision of data services. It offers the Aurora Driver which allows a vehicle to drive itself. The company was founded by Christopher Urmson, Sterling Anderson and James Andrew Bagnell in 2017 and is headquartered in Pittsburgh, PA.

Aurora Innovation Inc - Ordinary Shares - Class A

Aurora Innovation is surging as investors react to a major commercial partnership with a Berkshire Hathaway subsidiary, signaling a critical shift from R&D to large-scale autonomous freight revenue. The community is heavily focused on the company's rapid expansion of driverless routes and the increasing pressure on a substantial short position as institutional conviction in the stock grows.

Spitcoin is a community-driven cryptocurrency built on the Solana blockchain that powers a decentralized creator economy through the LimitlessFlo platform.  The project focuses on giving creators full control over their content and earnings by enabling instant monetization from day one—through tips, subscriptions, live streaming, and marketplace transactions—without the restrictions of traditional platforms like bans, algorithm suppression, or delayed payouts.  At its core, Spitcoin is about combining meme culture with real utility, creating a self-sustaining ecosystem where platform activity drives token demand, and token usage fuels platform growth.

SpitCoin

SpitCoin is gaining significant traction within the crypto community as a key utility token powering the Limitlessflo platform. Investors are actively discussing its potential alongside other emerging projects, highlighting bullish sentiment and growing whale activity surrounding the ecosystem.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is trending as investors position for the company's upcoming earnings, with the community closely tracking its role as foundational infrastructure for AI scaling and high-bandwidth memory. Traders are actively debating the sustainability of current valuations and the potential for a breakout based on capital equipment spending trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates

Janux Therapeutics (JANX) delivered earnings and revenue surprises of +21.83% and -75.11%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter...

How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%

The consensus price target hints at an 180.4% upside potential for Janux Therapeutics (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Janux Therapeutics (NASDAQ:JANX) Upgraded by Truist Financial to Strong-Buy Rating

Truist Financial upgraded Janux Therapeutics to a "strong-buy" rating in a research report on Monday...

JonesTrading Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price

JonesTrading cut their price target on shares of Janux Therapeutics from $50.00 to $28.00 and set a "buy" rating on the stock in a report on Tuesday...

<ul class="summary-bullets"><li>While durable responses were observed in select patients through extended follow-up, the overall magnitude and consistency of activity were not sufficient to support continued development relative to other pipeline programs, it said.&nbsp;</li><li>However, the experimental therapy demonstrated a differentiated tolerability profile with fewer gastrointestinal, dermatologic, and subcutaneous adverse events as compared to other drugs belonging to its category.&nbsp;</li><li>The company also clarified that the decision to discontinue JANX008 is program-specific and part of its efforts to prioritize parts of its portfolio.</li></ul>Shares of Janux Therapeutics, Inc. (JANX) edged up 1% after hours after the company said on Monday that it will discontinue development of its experimental program called JANX008 to focus its resources on its remaining pipeline.The company said that it came to the decision after completing early-stage trials across multiple solid tumor indications and an internal review of the data. While durable responses were observed in select patients through extended follow-up, the overall magnitude and consistency of activity were not sufficient to support continued development relative to other pipeline programs, it said.However, the experimental therapy demonstrated a differentiated tolerability profile with fewer gastrointestinal, dermatologic, and subcutaneous adverse events as compared to other drugs belonging to its category, the company said. Overall safety profile also allows for outpatient dosing, the company noted.The company also clarified that the decision to discontinue JANX008 is program-specific and part of its efforts to prioritize parts of its portfolio.“Our decision to discontinue JANX008 reflects the disciplined approach we take to advancing our pipeline,” said David Campbell, Ph.D., President and Chief Executive Officer of Janux. “We evaluate each program against a high bar for safety, activity, and differentiated profile. We prioritize resources toward programs that meet these criteria and offer opportunities to deliver best-in-class outcomes.”Janux is currently also evaluating other experimental drugs for the treatment of prostate cancer as well as autoimmune diseases. Earlier this month, the company said that it dosed the first participant in an early-stage study of JANX014, one of its candidates for prostate cancer.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around JANX fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.JANX stock has fallen 53% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/crmd-stock-jumps-as-antifungal-drug-clears-key-trial-for-2-billion-preventive-market/cZBNx6bRePY">CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Janux Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline

The company said that it came to the decision after completing early-stage trials across multiple solid tumor indications and an internal review of the data.

Equity

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further...

Will Acute Care Strength Help Universal Health Offset Q1 Rising Costs?

UHS heads into Q1 earnings with acute care and behavioral health growth, but rising labor and supply costs could cloud the outlook.

Will Higher Costs & Lower Occupancy Impact HCA's Q1 Earnings?

HCA Healthcare heads into Q1 earnings with higher costs, lower occupancy and shorter stays weighing on results despite revenue growth.

Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the fourteen ratings firms that are presently covering the company...

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

Janux Therapeutics Inc

Buying for a long-term investment

Buying for a short-term trade

Trading around the volatility

Avoiding it 

Cerebras ($CRBS) IPO day is Thursday, how are you playing it?  
 
Drop a comment with your strategy.

Current Price	$14.61
Prev Close	$14.41
Open	$14.27
Dividend Yield	0.00%
50-Day Moving Average	$14.42
Beta	1.41
Avg. Volume	1M
PE Ratio	-7.93

52-Week High	$35.34
52-Week Low	$12.12
Market Capitalization	$878.78M
EPS (Annual)	-$1.83
Price to Book	0.94
Revenue Per Employee	$91,743.12

JANX
Janux Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest JANX News

JANXJanux Therapeutics Inc